首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   14443篇
  免费   1293篇
  国内免费   42篇
耳鼻咽喉   119篇
儿科学   594篇
妇产科学   283篇
基础医学   1738篇
口腔科学   299篇
临床医学   1651篇
内科学   2816篇
皮肤病学   157篇
神经病学   1342篇
特种医学   753篇
外科学   2008篇
综合类   373篇
一般理论   18篇
预防医学   1360篇
眼科学   367篇
药学   1066篇
  1篇
中国医学   10篇
肿瘤学   823篇
  2021年   235篇
  2020年   151篇
  2019年   252篇
  2018年   307篇
  2017年   232篇
  2016年   248篇
  2015年   304篇
  2014年   385篇
  2013年   531篇
  2012年   808篇
  2011年   800篇
  2010年   466篇
  2009年   404篇
  2008年   714篇
  2007年   712篇
  2006年   708篇
  2005年   671篇
  2004年   699篇
  2003年   577篇
  2002年   606篇
  2001年   370篇
  2000年   351篇
  1999年   331篇
  1998年   243篇
  1997年   218篇
  1996年   224篇
  1995年   153篇
  1994年   170篇
  1993年   172篇
  1992年   301篇
  1991年   261篇
  1990年   214篇
  1989年   227篇
  1988年   212篇
  1987年   218篇
  1986年   188篇
  1985年   183篇
  1984年   139篇
  1983年   116篇
  1982年   95篇
  1981年   95篇
  1980年   101篇
  1979年   89篇
  1978年   87篇
  1977年   84篇
  1976年   94篇
  1974年   75篇
  1973年   95篇
  1972年   87篇
  1971年   73篇
排序方式: 共有10000条查询结果,搜索用时 625 毫秒
1.
2.
3.
4.
5.
PurposeOur purpose was to determine the effect of chemoradiotherapy (CRT) on patient-reported quality of life (QOL) for patients with intact pancreas cancer.Methods and MaterialsWe reviewed a prospective QOL registry for patients with intact, clinically localized pancreatic ductal adenocarcinoma treated with CRT between June 2015 and November 2018. QOL was assessed pre-CRT (immediately before CRT, after neoadjuvant chemotherapy) and at the completion of CRT with the Functional Assessment of Cancer Therapy-Hepatobiliary (FACT-Hep) and its component parts: FACT-General (FACT-G) and hepatobiliary cancer subscore (HCS). A minimally important difference from pre-CRT was defined as ≥ 6, 5, and 8 points for FACT-G, HCS, and FACT-Hep, respectively.ResultsOf 157 patients who underwent CRT, 100 completed both pre- and post-CRT surveys and were included in the primary analysis. Median age at diagnosis was 65 years (range, 23-90). National Comprehensive Cancer Network resectability status was resectable (3%), borderline resectable (40%), or locally advanced (57%). Folinic acid, 5-fluorouracil, irinotecan, and oxaliplatin (FOLFIRINOX) (75%) or gemcitabine and nab-paclitaxel (42%) were given for a median of 6 cycles (range, 0-42) before CRT. Radiation therapy techniques included 3-dimensional conformal (22%), intensity modulated photon (55%), and intensity modulated proton (23%) radiation therapy to a median dose of 50 Gy (range, 36-62.5). Concurrent chemotherapy was most commonly capecitabine (82%). Sixty-three patients (63%) had surgery after CRT. The mean decline in FACT-G, HCS subscale, and FACT-Hep from pre- to post-CRT was 3.5 (standard deviation [SD], 13.7), 1.7 (SD 7.8), and 5.2 (SD 19.4), respectively. Each of these changes were statistically significant, but did not meet the minimally important difference threshold. Pancreatic head tumor location was associated with decline in FACT-Hep. Nausea was the toxicity with the greatest increase from pre- to post-CRT by both physician-assessment and patient-reported QOL.ConclusionsFor patients with intact pancreatic adenocarcinoma, modern CRT is well tolerated with minimal decline in QOL during treatment.  相似文献   
6.
7.
8.
The treatment of melanoma has been markedly improved by the introduction of targeted therapies and checkpoint blockade immunotherapy. Unfortunately, resistance to these therapies remains a limitation. Novel anticancer therapeutics targeting the MCL1 anti-apoptotic protein have shown impressive responses in haematological cancers but are yet to be evaluated in melanoma. To assess the sensitivity of melanoma to new MCL1 inhibitors, we measured the response of 51 melanoma cell lines to the novel MCL1 inhibitor, S63845. Additionally, we assessed combination of this drug with inhibitors of the bromodomain and extra-terminal (BET) protein family of epigenetic readers, which we postulated would assist MCL1 inhibition by downregulating anti-apoptotic targets regulated by NF-kB such as BCLXL, BCL2A1 and XIAP, and by upregulating pro-apoptotic proteins including BIM and NOXA. Only 14% of melanoma cell lines showed sensitivity to S63845, however, combination of S63845 and I-BET151 induced highly synergistic apoptotic cell death in all melanoma lines tested and in an in vivo xenograft model. Cell death was dependent on caspases and BAX/BAK. Although the combination of drugs increased the BH3-only protein, BIM, and downregulated anti-apoptotic proteins such as BCL2A1, the importance of these proteins in inducing cell death varied between cell lines. ABT-199 or ABT-263 inhibitors against BCL2 or BCL2 and BCLXL, respectively, induced further cell death when combined with S63845 and I-BET151. The combination of MCL1 and BET inhibition appears to be a promising therapeutic approach for metastatic melanoma, and presents opportunities to add further BCL2 family inhibitors to overcome treatment resistance.  相似文献   
9.
10.
Marie Warrer Petersen  Tine Sylvest Meyhoff  Marie Helleberg  Maj-Brit Nørregaard Kjær  Anders Granholm  Carl Johan Steensen Hjortsø  Thomas Steen Jensen  Morten Hylander Møller  Peter Buhl Hjortrup  Mik Wetterslev  Gitte Kingo Vesterlund  Lene Russell  Vibeke Lind Jørgensen  Klaus Tjelle  Thomas Benfield  Charlotte Suppli Ulrik  Anne Sofie Andreasen  Thomas Mohr  Morten H. Bestle  Lone Musaeus Poulsen  Mette Friberg Hitz  Thomas Hildebrandt  Lene Surland Knudsen  Anders Møller  Christoffer Grant Sølling  Anne Craveiro Brøchner  Bodil Steen Rasmussen  Henrik Nielsen  Steffen Christensen  Thomas Strøm  Maria Cronhjort  Rebecka Rubenson Wahlin  Stephan Jakob  Luca Cioccari  Balasubramanian Venkatesh  Naomi Hammond  Vivekanand Jha  Sheila Nainan Myatra  Christian Gluud  Theis Lange  Anders Perner 《Acta anaesthesiologica Scandinavica》2020,64(9):1365-1375

Introduction

Severe acute respiratory syndrome coronavirus-2 has caused a pandemic of coronavirus disease (COVID-19) with many patients developing hypoxic respiratory failure. Corticosteroids reduce the time on mechanical ventilation, length of stay in the intensive care unit and potentially also mortality in similar patient populations. However, corticosteroids have undesirable effects, including longer time to viral clearance. Clinical equipoise on the use of corticosteroids for COVID-19 exists.

Methods

The COVID STEROID trial is an international, randomised, stratified, blinded clinical trial. We will allocate 1000 adult patients with COVID-19 receiving ≥10 L/min of oxygen or on mechanical ventilation to intravenous hydrocortisone 200 mg daily vs placebo (0.9% saline) for 7 days. The primary outcome is days alive without life support (ie mechanical ventilation, circulatory support, and renal replacement therapy) at day 28. Secondary outcomes are serious adverse reactions at day 14; days alive without life support at day 90; days alive and out of hospital at day 90; all-cause mortality at day 28, day 90, and 1 year; and health-related quality of life at 1 year. We will conduct the statistical analyses according to this protocol, including interim analyses for every 250 patients followed for 28 days. The primary outcome will be compared using the Kryger Jensen and Lange test in the intention to treat population and reported as differences in means and medians with 95% confidence intervals.

Discussion

The COVID STEROID trial will provide important evidence to guide the use of corticosteroids in COVID-19 and severe hypoxia.
  相似文献   
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号